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Abstract No fully effective approved drug therapy exists
for Cryptosporidium infections of immunocompetent and
immunocompromised patients. Here, we investigated 11
benzimidazole derivatives carrying substituted thioalkyl
and thiobenzyl groups at position 2 of benzimidazole
nucleus and additional substituents at the benzene part of
benzimidazole for inhibition of the in vitro growth of the
intestinal protozoan parasite, Cryptosporidium parvum.
Three of them, i.e., 5-carboxy-2-(4-nitrobenzylthio)-
1H-benzimidazole, 5,6-dichloro-2-(4-nitrobenzylthio)-
1H-benzimidazole, and 4,6-dichloro-2-(4-nitrobenzylthio)-
1H-benzimidazole, (compounds 5, 7, and 8) were the most
active (IC50 28–31 μM). The concentration of compounds
5, 7, and 8 that caused 50% growth inhibition in human
enterocytic HCT-8 cells by a quantitative alkaline phospha-
tase immunoassay was comparable with those obtained for
paromomycin.
Introduction
Cryptosporidium parvum is an important apicomplexan
protozoan pathogen that significantly contributes to diar-
rheal disease in both humans and animals (Downey et al.
2008; Fayer 2004; Graczyk et al. 1997). Throughout the
world in immunocompetent hosts, Cryptosporidium infec-
tions are generally restricted to the intestinal epithelium,
causing acute and self-limiting gastroenteritis. However, for
HIV/AIDS patients and other immunocompromised indi-
viduals (organs transplant patients), such infection can
result in life-threatening diarrheal disease (Ventura et al.
1997). Recently, only nitazoxanide, a nitrothiazole benza-
mide, was approved by the Food and Drug Administration
(FDA) for the treatment of cryptosporidiosis in immuno-
competent adults and children over 1 year old (Anderson
and Curann 2007). However, this drug is not fully successful
for all cases of cryptosporidiosis. Another drug, paromomy-
cin, is well-known as a compound to treat C. parvum
infections in animals and cell cultured models. Because
Cryptosporidium currently and continuously causes over half
of the reported waterborne disease outbreaks associated with
exposure in chlorinated public swimming pool water
(Dziuban et al. 2006;I j a ze ta l .2000; Sunderland et al.
2007), research on new compounds to treat this disease is in
progress.
The benzimidazole nucleus is present in numerous
antiparasitic, fungicidal anthelmintic, and anti-
inflammatory drugs (Andrzejewska et al. 2004; Bennamane
et al. 2009; Kazimierczuk et al. 2002). Albendazole,
mebendazole, and benzimidazole carbamates affect the
cycloskeleton and interact with tubulin of Giardia and
other parasitic protozoa (Reynoldson et al. 1992). The
various benzimidazole derivatives were investigated as
potential antiprotozoan drugs, mainly against Giardia,
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et al. 2010; Hernández-Luis et al. 2010). Therefore, we
decided to provide pilot screening tests using the benz-
imidazole derivatives of our laboratory resources against
C. parvum. Of all tested compounds, the most promising
appeared to be derivatives of 2-thiobenzimidazole-carrying
additive substituents on the heterocyclic ring as well on the
S-alkyl-benzyl chains. The major objective of the present
study was the search for novel “leading structure” of
heterocyclic compounds that would show promise as
anticryptosporidial agents.
Materials and methods
Compounds Paromomycin was purchased from MP Bio-
medicals (Solon, OH, USA) and was diluted in water just
prior to use. The tested compounds were obtained according
the methods previously described (Kazimierczuk and Pinna
2004, 2005;N a r k h e d ee ta l .2007; Pagano et al. 2004).
C. parvum oocysts C. parvum (Iowa isolate) oocysts were
obtained through experimental infection of a female
Holstein calf. The protocol for animal infection was
approved by the animal care and use committee of the
Cornell University, College of Veterinary Medicine, Ithaca,
New York, USA. The oocysts were extracted from the feces
using continuous-flow centrifugation, purified by cesium
chloride gradient centrifugation, and stored at 4°C in
phosphate-buffered saline (PBS) (pH 7.4) Fig. 1.
Compound activity in cell culture HCT-8 cells were
obtained from the American Type Culture Collection
(Manassas, VA, USA) and maintained in RPMI 1640
medium supplemented with 10% Opti-MEM (GIBCO-
BRL, Grand Island, NY, USA), 2% fetal bovine serum,
and 2 mM L-glutamine. To determine in vitro drug efficacy,
a quantitative alkaline phosphatase immunoassay was used
to measure parasite growth inhibition in cell culture as
described previously (Gargala et al. 1999; Woods et al.
1995). Briefly, 96-well, flat-bottom microtiter plates were
seeded with 5×10
4 HCT-8 cells 24 h prior to infection. For
infection, the maintenance medium was removed and
5×10
3 oocysts were added to wells in 100 μl of RPMI
1640 supplemented with 10% fetal bovine serum and
0.05% bile salts. After incubation at 37°C for 90 min to
induce excystation and to allow cell invasion, cells were
washed once with warm PBS to remove unexcysted oocysts
and free sporozoites. Negative control wells to measure
background absorbance received 5×10
3 nonviable oocysts
subjected to 5 cycles of freezing in liquid nitrogen and
thawing in a 37°C water bath. Drugs were diluted to
appropriate concentrations (Fig. 2) and added to cells in
150 μl of parasite growth medium. Paromomycin was used
for comparison. Each drug concentration was tested in
triplicates in two independent experiments. Plates were first
incubated for 48 h at 37°C in 5% CO2–95% humidified air
incubator, and then fixed in 8% formalin for 2 h at 22°C.
After fixation, plates were washed three times with PBS
and then blocked for 1 h with 300 μl of a blocking solution
consisting of 5% bovine serum albumin (BSA) and 0.002%
Tween 20 in PBS. Rat anti-Cryptosporidium polyclonal
sera were diluted 1:500 in a solution of 1% BSA–0.002%
Tween 20 in PBS, and 50 μl was added to each well. After
30-min incubation at 22°C, the wells were washed three
times with PBS, and 50 μl of a horseradish peroxidase-
conjugated goat anti-rat secondary antibody diluted 1:2,000
in 1% BSA–0.002% Tween 20–PBS was added to each
well. After 20 min, plates were washed three times with
PBS, and 100 μlo fa3 , 3 ′,5,5′-tetramethylbenzidine
N
N
S
H
R5
R1
R2
R3
R4
1   R1, R2, R3, R4 = H                   R5 = n-C4H9                   [Narkhede et al. 2007]
2   R1,R3 = Cl, R2, R4 = H             R5 = CH2CH2OH                [Andrzejewska et al. 2004]
3   R1, R3 = Cl, R2, R4 = H            R5 = (CH2)3N(CH3)2               [Andrzejewska et al. 2004]
4   R1, R2,R 3, R4 = H                    R5 = benzyl         [Narkhede et al. 2007]
5   R1,R 3, R4 = H, R2 = COOH     R5 = 4-nitrobenzyl              [Kazimierczuk et al. 2002]
6   R1, R2, R3 = H, R2 = COOH     R5 = 3,4-dichlorobenzyl     [Kazimierczuk et al. 2002]
7   R1, R4 = H, R2, R3 = Cl,           R5 = 4-nitrobenzyl              [Kazimierczuk et al. 2002]
8   R1, R3 = Cl,  R2, R4 = H           R5 = 4-nitrobenzyl              [Kazimierczuk et al. 2002]
9   R1, R3 = Br, R2, R4 = H            R5 = 3,5-dinitrobenzyl        [Kazimierczuk et al. 2005]
10 R1, R3, R4 = H, R2 = I            R5 = 3,5-dinitrobenzyl        [Kazimierczuk et al. 2005]
11 R1, R2, R3, R4 = Br                  R5 = 4-nitrobenzyl              [Pagano et al. 2004]
Fig. 1 Structures of tested
benzimidazole derivatives
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USA) solution was added. After 10 min, 100 μl of stop
solution (Kirkegaard & Perry Laboratories) was added to
each well, and plates were read at 450 nm using an enzyme-
linked immunosorbent assay microplate reader (Molecular
Devices, Sunnyvale, CA, USA).
The background absorbance reading taken from wells
receiving freeze-thawed oocysts was subtracted from all
absorbance readings from drug-treated and control wells,
and the percentage of growth inhibition was calculated
as 1   mean A450 of infected wells with drug=mean A450 of ð ½
infected wells without drugÞ    100%. The mean values
obtained from triplicate readings in two independent
experiments were assessed for their significance by the
nonparametric test, i.e., median t test. Significance was
considered at P<0.05.
Results and discussion
The effect of paromomycin and 11 different benzimidazole
derivatives on parasite growth were investigated in cell
culture by exposure of C. parvum-infected cells to the
antimicrobial compounds for 48 h. Paromomycin was used
as a reference compound.
The present study demonstrated that the 9 of 11 tested
benzimidazole derivatives reduced the number of develop-
mental stages of C. parvum in vitro. In particular,
compounds 5, 7, and 8 were comparable to paromomycin
in inhibiting pathogen growth. Paromomycin is commonly
used to treat Cryptosporidium-infected animals and immu-
nocompetent humans. However, this drug is expensive and
produces serious side effects, thus cannot be used for
immunocompromised individuals with weakened liver
functions. Thus, variously substituted benzimidazoles on
the benzene nucleus carrying additional nitrobenzylthio
substituents at position 2 could be further tested for use in
the treatment of cryptosporidiosis in both immunocompe-
tent and immunocompromised individuals.
The mechanisms of Cryptosporidium growth inhibition
by the compounds tested in the present study are not clear.
However, it is most likely related to the absorption of the
drug through Cryptosporidium trophozoite membranes. It is
noteworthy that compounds 1 and 4 being “core structures”
for other derivatives were essentially nonactive in the test
experiments with their inhibitory concentration values
significantly elevated in comparison to paromomycin
(median t test; P<0.05) (Fig. 2). However, introduction of
the halogen atoms or carboxyl group onto benzene part of
benzimidazole enhances the efficacy of investigated com-
pounds against Crytosporidium. Also, the presence of nitro
group or chlorine atoms in the benzylthio part of molecule
positively affected antiparasitic activity of the compounds.
For this study, we selected only the compounds which have
some structural elements typical for nitoxazide (nitrogroup
in the side ring) or halogen atoms (chlorophenyltriazole
derivatives) (Sharling et al. 2010). It seems also that in the
alkylthio residue, the additional functional group is neces-
sary as observed based on anti-C. parvum activity obtained
by compounds 1, 2, and 3. Further studies are necessary to
reveal and substantiate the function of the benzimidazole
derivatives as prospective anticrysporidial drug candidates.
Testing of the efficacy of the benzimidazole derivative
compounds in vitro against developmental stages of
Cryptosporidium is the first step in drug testing. Based on
the ID50 values obtained in the present study for these 11
compounds, we conclude that all produced an elevated
level of effectiveness that warrants the next phase of
investigation to focus on toxicity and animal infection
testing. However, our attention will be particularly focused
on the three compounds, i.e., 5, 7, and 8 since their efficacy
was shown to be superior to paromomycin.
The ideal drug for treatment of cryptosporidiosis or
any other intestinal protozoa infection in immunocompe-
tent and immunocompromised patients should be easy
absorbable by the intestinal epithelium (which is site of
Cryptosporidium infection) and should be effective at low
dosage without producing side effects (Downey et al.
2009). However, if a drug does not produce side effects,
the dose and frequency of treatment are irrelevant. The
compounds tested in the present study are not water-
soluble but soluble in lipids which assures their: (1)
emulsification in the intestinal lumen; (2) easy absorption
Fig. 2 Inhibitory concentration (IC50) of paromomycin and tested
benzimidazole derivatives and paromomycin (p). Inhibitory concen-
tration of derivatives 1 and 2 significantly elevated as compared to
paromomycin (median t test; P<0.05)
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effect on Cryptosporidium developmental stages covering
intestinal epithelium microvilli.
Because there are not enough directly relevant studies and
results for treatment of C. parvum infections and this genus
includes another human infectious species, Cryptosporidium
hominis (Xiao et al. 2001), we will test the compounds in
animal models. Anti-diarrheal medicine may retard diarrhea,
but a health care provider should be consulted before such
medicine is administered (Downey et al. 2008). Nitazox-
anide is FDA-approved for treatment of diarrhea caused by
Cryptosporidium in humans with healthy immune systems
and is available by prescription. However, the effectiveness
of nitazoxanide in immunosuppressed individuals is unclear.
HIV positive individuals who suspect they have crypto-
sporidiosis should contact their health care provider. For
those persons with AIDS, anti-retroviral therapy that
improves the immune status will also decrease or eliminate
symptoms of cryptosporidiosis. However, even if symp-
toms disappear, cryptosporidiosis is often not curable and
the symptoms may return if the immune status worsens.
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